AC Immune SANASDAQ:ACIU
- LAST PRICE2.3700
- TODAY'S CHANGE (%)-0.0100 (-0.4202%)
- Bid / Lots2.3300/ 1
- Ask / Lots2.6900/ 1
- Open / Previous Close2.4000 / 2.3800
- Day Range
- 52 Week Range
- Volume322,914
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ACIU |
|---|---|---|
| 09:32 ET | 728 | 2.46 |
| 09:48 ET | 14100 | 2.43 |
| 09:50 ET | 5600 | 2.44 |
| 09:52 ET | 14300 | 2.43 |
| 09:54 ET | 300 | 2.44 |
| 10:32 ET | 200 | 2.41 |
| 10:35 ET | 100 | 2.41 |
| 10:37 ET | 2923 | 2.44 |
| 10:46 ET | 100 | 2.41 |
| 11:00 ET | 100 | 2.41 |
| 11:02 ET | 14666 | 2.46 |
| 11:04 ET | 14007 | 2.41 |
| 11:06 ET | 2851 | 2.37 |
| 11:08 ET | 2911 | 2.36 |
| 11:31 ET | 500 | 2.415 |
| 11:36 ET | 100 | 2.39 |
| 11:38 ET | 1000 | 2.3953 |
| 11:40 ET | 100 | 2.381 |
| 12:02 ET | 800 | 2.39 |
| 12:07 ET | 300 | 2.38 |
| 12:16 ET | 800 | 2.35 |
| 12:18 ET | 218 | 2.37 |
| 12:21 ET | 105 | 2.375 |
| 12:23 ET | 210 | 2.375 |
| 12:45 ET | 200 | 2.37 |
| 12:48 ET | 200 | 2.37 |
| 12:50 ET | 100 | 2.371 |
| 12:54 ET | 100 | 2.38 |
| 12:57 ET | 400 | 2.37 |
| 01:15 ET | 100 | 2.341 |
| 01:33 ET | 700 | 2.39 |
| 01:44 ET | 100 | 2.36 |
| 02:36 ET | 330 | 2.4 |
| 03:20 ET | 400 | 2.3508 |
| 03:25 ET | 6330 | 2.35 |
| 03:54 ET | 300 | 2.34 |
| 03:56 ET | 376 | 2.37 |
| 03:59 ET | 1221 | 2.37 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
AC Immune SA | 236.1M | -3.4x | --- |
TriSalus Life Sciences Inc | 272.9M | -5.6x | --- |
Fennec Pharmaceuticals Inc | 250.4M | -15.0x | --- |
Werewolf Therapeutics Inc | 279.2M | -6.1x | --- |
Uniqure NV | 227.2M | -0.7x | --- |
MeiraGTx Holdings PLC | 313.6M | -3.1x | --- |
Company Information
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Contact Information
- Headquarters
- EPFL Innovation Park, Building BLAUSANNE, Switzerland 1015
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Douglas Williams
- Chief Executive Officer, Co-Founder, Director
- Andrea Pfeifer
- Chief Financial Officer, Vice President - Finance
- Christopher Roberts
- Chief Technical Operations Officer
- Piergiorgio Donati
- Chief Human Resource Officer
- Howard Donovan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $236.1M |
|---|---|
Revenue (TTM) | $16.2M |
Shares Outstanding | 99.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.05 |
EPS | $-0.70 |
Book Value | $1.78 |
P/E Ratio | -3.4x |
Price/Sales (TTM) | 14.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -362.30% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
